# AI Order and Prescription Suggestions: 2025 Capability Analysis

## Executive Summary

AI-powered order and prescription suggestion capabilities have reached significant maturity in 2025, with ambient clinical intelligence (ACI) vendors expanding beyond documentation into automated order staging, prescription generation, and clinical decision support. The market is projected at $37.2 billion globally, with 60% of healthcare providers expected to use AI-driven medical scribes by year-end.

Key developments include:
- **Suki** launched industry-first ambient orders staging (April 2025)
- **Abridge** expanded orders capabilities through Epic Workshop partnership
- **Nuance DAX** embedded order suggestions directly in Epic workflows
- **CMS** launched AI prior authorization pilot (WISeR) in 6 states
- **FDA** issued comprehensive AI lifecycle management guidance (January 2025)
- **EU AI Act** high-risk medical device provisions coming into force

---

## 1. Ambient Order Capture

### 1.1 Nuance DAX Copilot Order Suggestions

**How It Works:**
- DAX Copilot automatically captures **over a dozen order types** during clinician-patient conversations
- With supported EHRs (Epic, others), orders are directly entered into the EHR order module
- Fully embedded in Epic's Haiku workflow for seamless clinician experience

**Key Capabilities:**
| Feature | Description |
|---------|-------------|
| Order Type Coverage | Labs, imaging, referrals, medications, procedures, follow-ups |
| EHR Integration | Direct staging in Epic order module |
| Clinician Review | Orders presented for verification before submission |
| Note Coordination | Orders synchronized with clinical note content |

**2025 Developments:**
- Microsoft unifying DAX Copilot into **Dragon Copilot** (GA December 2025 US)
- Expanding to Austria, France, Germany, Ireland (October 2025)
- Belgium/Netherlands rollout early 2026

**Impact Metrics:**
- 70% reduction in burnout feelings
- 50% reduction in documentation time

**Sources:**
- [Nuance DAX Copilot](https://www.nuance.com/healthcare/dragon-ai-clinical-solutions/dax-copilot.html)
- [Healthcare IT News - Nuance AI Embedded in Epic](https://www.healthcareitnews.com/news/nuance-ai-copilot-now-fully-embedded-epic-ehr)

---

### 1.2 How Orders Are Extracted from Conversation

**Technical Approach:**

The MEDIQA-OE 2025 shared task established the first benchmark for medical order extraction from doctor-patient conversations, revealing current AI capabilities and limitations:

```
Order Extraction Pipeline:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Audio Stream â†’ ASR Transcription â†’ NLP Processing â†’ Orders    â”‚
â”‚                                                                 â”‚
â”‚  1. Speech-to-text conversion (real-time)                       â”‚
â”‚  2. Speaker diarization (identify clinician vs patient)         â”‚
â”‚  3. Medical entity recognition (drugs, tests, procedures)       â”‚
â”‚  4. Intent classification (order vs discussion vs history)      â”‚
â”‚  5. Order type categorization (medication, lab, imaging, etc.)  â”‚
â”‚  6. Structure extraction (dose, frequency, duration, route)     â”‚
â”‚  7. EHR mapping (code to formulary items)                       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Current Performance (MEDIQA-OE 2025 Results):**
| Metric | Top Score | Gap |
|--------|-----------|-----|
| Match F1 Score | 81.8% | ~18% improvement needed |
| Description Accuracy | ~65% | Lags 15-18% behind match |
| Provenance Extraction | ~65% | Lags 15-18% behind match |

**Order Types Commonly Extracted:**
- Medications (new prescriptions, refills, discontinuations)
- Laboratory tests (bloodwork, panels, cultures)
- Imaging studies (X-ray, CT, MRI, ultrasound)
- Referrals to specialists
- Procedures and treatments
- Follow-up appointments
- Patient instructions

**Sources:**
- [MEDIQA-OE 2025 Overview](https://arxiv.org/html/2510.26974)
- [EXL Health MEDIQA-OE Evaluation](https://arxiv.org/html/2511.10583v1)

---

### 1.3 Direct EHR Order Entry

**Vendor Integration Approaches:**

| Vendor | EHR | Integration Method | Status (2025) |
|--------|-----|-------------------|---------------|
| **Nuance DAX** | Epic | Epic Workshop native integration | GA |
| **Suki** | athenahealth | API-based order staging | GA |
| **Suki** | Epic | API integration | Coming soon |
| **Suki** | Oracle Health | API integration | Coming soon |
| **Suki** | MEDITECH | Expanse Documentation APIs | GA (July 2025) |
| **Abridge** | Epic | Workshop co-development | In development |
| **Ambience** | athenahealth | Marketplace integration | GA |

**Suki's Ambient Orders Staging (April 2025):**
- First vendor to offer prescription order generation from ambient visits
- Clinicians speak prescription orders during encounters
- System structures, codes, and stages orders automatically
- Minimizes manual input and verification processes

**Abridge Order Entry Development:**
- Co-developing order entry with Epic through Workshop program
- Orders discussed during conversations captured for staging
- Part of broader EHR-integrated actionable outputs

**Sources:**
- [Suki Ambient Orders Staging](https://www.suki.ai/news/suki-unveils-industry-first-ambient-orders-staging-for-its-ai-assistant/)
- [Suki MEDITECH Integration](https://www.suki.ai/news/suki-becomes-first-to-integrate-ambient-ai-with-meditech-expanse-documentation-apis/)
- [Abridge Orders Feature](https://www.fiercehealthcare.com/health-tech/abridge-launches-gen-ai-tool-inpatient-clinicians-adds-outpatient-orders-feature)

---

### 1.4 Verification Workflow

**Clinician Review Requirements:**

All ambient AI order systems require **mandatory clinician verification** before order submission:

```
Verification Workflow:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  AI-Suggested Orders                                            â”‚
â”‚  â”œâ”€â”€ Medications                                                â”‚
â”‚  â”‚   â””â”€â”€ [Review] [Modify] [Accept] [Reject]                   â”‚
â”‚  â”œâ”€â”€ Labs                                                       â”‚
â”‚  â”‚   â””â”€â”€ [Review] [Modify] [Accept] [Reject]                   â”‚
â”‚  â””â”€â”€ Imaging                                                    â”‚
â”‚      â””â”€â”€ [Review] [Modify] [Accept] [Reject]                   â”‚
â”‚                                                                 â”‚
â”‚  â”Œâ”€ Clinician Actions â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ â€¢ Review each suggested order                            â”‚   â”‚
â”‚  â”‚ â€¢ Modify parameters (dose, frequency, quantity)          â”‚   â”‚
â”‚  â”‚ â€¢ Accept to stage for signing                            â”‚   â”‚
â”‚  â”‚ â€¢ Reject inappropriate suggestions                       â”‚   â”‚
â”‚  â”‚ â€¢ Sign/authenticate to submit                            â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Key Verification Principles:**
- Orders remain **suggestions** until clinician approval
- Clinician maintains final **signing authority**
- System tracks all modifications for audit trail
- No automated order submission without human review

---

## 2. Order Decision Support

### 2.1 Appropriate Use Criteria (AUC)

**CMS AUC Program Status:**

As of January 1, 2025, **CMS rescinded the AUC program** regulations (42 CFR 414.94), citing inability to operationalize real-time claims-based reporting requirements.

**Historical Context:**
- Program intended to require AUC consultation for advanced imaging
- Implementation challenges with claims-based verification
- Contractor edits related to AUC removed effective January 2025

**AI-Assisted AUC Tools Remain Active:**

Despite CMS program changes, clinical decision support for appropriate use remains in use:

| System | Vendor | Capabilities |
|--------|--------|--------------|
| CareSelect Imaging | Change Healthcare | 15,000+ AUC across all modalities |
| ACR Select | American College of Radiology | Evidence-based imaging guidelines |
| AI-Enhanced CDS | Various | Translates free-text to structured indications |

**AI-Assisted Indication Selection Study Results:**
- AI tool implementation increased scored orders from 30% to 52% (p < .001)
- 59% utilization rate when ordering imaging with CDS
- Nationally, 43-80% of orders remain unscored
- Up to 70% of unscored orders attributed to free-text indication entry

**Effectiveness Limitations:**
> "CDS alerts triggered by low appropriate use criteria scores caused minimal increase in time spent on imaging order entry, but had a relatively marginal impact on imaging study selection."

**Sources:**
- [CMS AUC Program Rescission](https://www.cms.gov/files/document/r12508otn.pdf)
- [ACR Clinical Decision Support](https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Clinical-Decision-Support)
- [AI-Assisted AUC Study](https://pubmed.ncbi.nlm.nih.gov/37390881/)

---

### 2.2 Cost-Effective Alternatives

**AI-Driven Cost Optimization:**

AI CDSS assists in cost-effective prescribing by:

| Capability | Description |
|------------|-------------|
| Generic Substitution | Recommending therapeutically equivalent generics |
| Formulary Alignment | Suggesting covered alternatives |
| Cost Comparison | Displaying out-of-pocket costs at point of prescribing |
| Step Therapy Guidance | Recommending first-line agents before expensive alternatives |
| Biosimilar Suggestions | Identifying biosimilar options for biologics |

**Real-Time Prescription Benefit (RTPB) Tools:**

```
RTPB Transaction Flow:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Provider selects drug in EHR                                    â”‚
â”‚           â†“                                                      â”‚
â”‚  Request sent to intermediary (Surescripts, others)              â”‚
â”‚           â†“                                                      â”‚
â”‚  PBM returns:                                                    â”‚
â”‚  â€¢ Coverage status                                               â”‚
â”‚  â€¢ Estimated out-of-pocket cost                                  â”‚
â”‚  â€¢ Prior authorization requirements                              â”‚
â”‚  â€¢ Lower-cost therapeutic alternatives                           â”‚
â”‚  â€¢ Preferred pharmacy options                                    â”‚
â”‚           â†“                                                      â”‚
â”‚  Provider reviews alternatives and selects optimal choice        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**RTPB Effectiveness (Johns Hopkins Study):**
- 78% of RTPB recommendations resulted in more favorable coverage status
- 67% of changes resulted in more favorable prior authorization status

**Regulatory Requirements:**
- CMS requires Medicare Part D sponsors to implement RTBTs (since January 2021)
- NCPDP RTPB standard version 13 mandatory by January 1, 2027

**Sources:**
- [Surescripts Real-Time Prescription Benefit](https://surescripts.com/what-we-do/real-time-prescription-benefit)
- [RTBT Implementation Study](https://www.ajmc.com/view/implementation-and-cost-validation-of-a-real-time-benefit-tool)

---

### 2.3 Insurance Coverage Checking

**Automated Eligibility and Benefits Verification:**

Modern prescribing systems integrate insurance verification:

| Check Type | AI/Automation Role |
|------------|-------------------|
| Eligibility | Real-time verification of active coverage |
| Formulary Status | Tier classification and coverage level |
| Prior Auth Required | Flagging drugs needing PA |
| Step Therapy | Identifying required preceding medications |
| Quantity Limits | Alerting to coverage restrictions |
| Specialty Pharmacy | Routing to required pharmacies |

---

### 2.4 Prior Authorization Prediction

**AI Prior Auth Prediction Capabilities:**

AI predicts likelihood of approval and guides optimal treatment selection:

```
PA Prediction Model:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Inputs:                                                      â”‚
â”‚  â€¢ Historical approval/denial data                            â”‚
â”‚  â€¢ Patient diagnosis codes                                    â”‚
â”‚  â€¢ Proposed treatment/drug                                    â”‚
â”‚  â€¢ Insurance plan characteristics                             â”‚
â”‚  â€¢ Supporting documentation                                   â”‚
â”‚                     â†“                                         â”‚
â”‚  AI Model Outputs:                                            â”‚
â”‚  â€¢ Approval probability score                                 â”‚
â”‚  â€¢ Recommended documentation                                  â”‚
â”‚  â€¢ Alternative treatments likely to be approved               â”‚
â”‚  â€¢ Expected turnaround time                                   â”‚
â”‚  â€¢ Appeal likelihood if denied                                â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Medicare WISeR Pilot (2025-2031):**

CMS launched the **Wasteful and Inappropriate Service Reduction (WISeR)** model:

- **Launch:** January 2026
- **Duration:** Through 2031
- **States:** New Jersey, Ohio, Oklahoma, Texas, Arizona, Washington
- **Technology:** AI/ML with human clinical review
- **Purpose:** Ensure timely and appropriate Medicare payment

**Vendor Market (2025):**

Top AI prior authorization vendors include:
1. Olive AI
2. Rhyme Health
3. Waystar
4. Infinitus
5. Cohere Health

**Industry Metrics:**
- Prior authorization costs US healthcare **$41.4-55.8 billion annually**
- Physicians complete **39 prior authorizations/week** (13+ hours staff time)
- 89% of doctors report PA contributes to burnout
- One insurer reported AI made PA process **1,400x faster**

**Concerns:**
- 61% of physicians concerned AI increases denials
- Reports of AI denial rates 16x higher than typical
- Connecticut introduced 2025 bill barring AI-only coverage decisions

**Sources:**
- [CMS WISeR Model](https://www.cms.gov/priorities/innovation/innovation-models/wiser)
- [Medicare AI PA Pilot](https://www.statnews.com/2025/11/06/medicare-wiser-prior-authorization-pilot-tech-vendors/)
- [AMA AI PA Concerns](https://www.ama-assn.org/practice-management/prior-authorization/how-ai-leading-more-prior-authorization-denials)
- [AI PA Vendors 2025](https://innovaccer.com/blogs/top-5-ai-vendors-for-prior-authorization-2025)

---

## 3. E-Prescribing

### 3.1 AI-Assisted Prescribing

**Current AI Prescribing Capabilities:**

| Capability | Maturity | Vendor Examples |
|------------|----------|-----------------|
| Prescription from ambient | Emerging | Suki (GA April 2025) |
| Drug selection assistance | Mature | Multiple CDSS vendors |
| Dosing recommendations | Mature | Various platforms |
| Interaction checking | Mature | Micromedex, Clinical Pharmacology |
| Allergy verification | Mature | EHR-native |
| Formulary guidance | Mature | RTPB tools |
| Therapeutic alternatives | Mature | CDSS platforms |

**Suki Prescription Order Generation:**
- Clinicians speak prescription orders during patient encounters
- System structures and codes orders automatically
- Stages orders for review and signature
- Initial launch on athenahealth, expanding to Epic, Oracle Health, MEDITECH

---

### 3.2 Drug Selection Assistance

**AI-Driven Selection Support:**

```
Drug Selection Decision Support:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Patient Context:                                             â”‚
â”‚  â€¢ Diagnosis/indication                                       â”‚
â”‚  â€¢ Comorbidities                                              â”‚
â”‚  â€¢ Current medications                                        â”‚
â”‚  â€¢ Allergies                                                  â”‚
â”‚  â€¢ Renal/hepatic function                                     â”‚
â”‚  â€¢ Age/weight                                                 â”‚
â”‚  â€¢ Insurance coverage                                         â”‚
â”‚                     â†“                                         â”‚
â”‚  AI Recommendations:                                          â”‚
â”‚  â€¢ First-line therapy options                                 â”‚
â”‚  â€¢ Evidence-based alternatives                                â”‚
â”‚  â€¢ Patient-specific contraindications                         â”‚
â”‚  â€¢ Cost-optimized selections                                  â”‚
â”‚  â€¢ Guideline concordance scoring                              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Pathway Launch (May 2025):**
- Integrated drug reference and interaction checker
- AI-powered medical knowledge platform
- Comprehensive medication information for 2,000+ drugs
- Interaction screening within same interface

---

### 3.3 Dosing Suggestions

**AI Precision Dosing Advances:**

**PRECISE CURATE.AI Trial (February 2025):**
- Adaptive "digital-twin" dosing platform
- Safely embedded in routine solid-tumor care
- **97% clinician acceptance rate**
- **20% average drug-dose reductions** while maintaining efficacy

**Hybrid PK/PD + ML Models:**

Modern dosing systems combine:
- Classical pharmacokinetic/pharmacodynamic frameworks
- Machine learning personalization
- Real-time adjustment as new lab/sensor data flows in
- Model-Informed Precision Dosing (MIPD) platforms

**Dosing Decision Support Functions:**
| Function | Description |
|----------|-------------|
| Weight-based dosing | Automatic calculations |
| Renal adjustment | GFR-based dose modification |
| Hepatic adjustment | Child-Pugh score integration |
| Age-based dosing | Pediatric/geriatric considerations |
| Therapeutic drug monitoring | Target concentration guidance |
| Loading dose calculation | For drugs requiring loading |

**Sources:**
- [AI Precision Dosing](https://wirelesslifesciences.org/2025/05/ai-drug-dosing-algorithms/)
- [AI Clinical Decision Support Systems](https://sciencedirect.com/science/article/pii/S2212958825000886)

---

### 3.4 Drug Interaction Checking

**AI-Enhanced Interaction Detection:**

**Current AI DDI Capabilities:**
- Transformer models (DrugBERT, BioBERT) for semantic understanding
- Natural language processing for literature mining
- Early identification of emerging interactions before formal documentation
- Polypharmacy risk assessment for elderly/chronic disease patients

**Alert Fatigue Problem:**

Traditional CDSS generates high alert volumes with limited clinical relevance:
- Override rates as high as **96%**
- Most alerts lack clinical significance
- Leads to alert fatigue and dismissal of important warnings

**AI Optimization Approaches:**
| Approach | Method |
|----------|--------|
| Predictive response | Predict which alerts physicians will accept vs. override |
| Severity triage | Prioritize high-risk interactions |
| Context-aware | Filter based on patient-specific risk factors |
| Suppression learning | Learn which low-risk combinations to suppress |

**LLM Performance Evaluation (2025):**

Comparison of ChatGPT, Gemini, and Copilot for DDI screening:

| Platform | Sensitivity | Specificity | F1 Score |
|----------|-------------|-------------|----------|
| Gemini | 0.697 | - | 0.1933 |
| ChatGPT | - | 0.868 | 0.2520 |
| Copilot | - | - | 0.1153 |

**Conclusion:** No current LLM achieves required precision/sensitivity for standalone clinical DDI screening. Outputs require professional validation.

**Sources:**
- [AI DDI Research](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1618701/full)
- [AI Medication Alert Optimization](https://academic.oup.com/jamia/article/31/6/1411/7654019)
- [LLM DDI Evaluation](https://www.sciencedirect.com/science/article/pii/S2667276625000964)

---

## 4. Vendor Capabilities

### 4.1 Nuance Orders in Epic

**Integration Architecture:**

```
Nuance DAX Copilot + Epic Integration:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Haiku Mobile App                                               â”‚
â”‚  â”œâ”€â”€ Ambient recording during encounter                         â”‚
â”‚  â”œâ”€â”€ Real-time transcription                                    â”‚
â”‚  â””â”€â”€ DAX Copilot processing                                     â”‚
â”‚                     â†“                                           â”‚
â”‚  Epic Order Module                                              â”‚
â”‚  â”œâ”€â”€ Suggested orders staged for review                         â”‚
â”‚  â”œâ”€â”€ Clinician verification workflow                            â”‚
â”‚  â”œâ”€â”€ One-click acceptance or modification                       â”‚
â”‚  â””â”€â”€ Audit trail maintained                                     â”‚
â”‚                     â†“                                           â”‚
â”‚  Epic Cosmos Database                                           â”‚
â”‚  â””â”€â”€ Learning from outcomes across network                      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Epic Workshop Partnership:**
- Strategic co-development relationship
- Deep EHR integration beyond third-party APIs
- Shared innovation roadmap
- Native workflow embedding

**Dragon Copilot Unification (2025):**
- DAX Copilot capabilities unified under Dragon Copilot brand
- Broader clinical assistant functionality
- General availability: December 2025 (US)
- International expansion through 2026

---

### 4.2 Suki Orders Expansion

**Timeline of Suki Orders Development:**

| Date | Milestone |
|------|-----------|
| April 2025 | Industry-first ambient orders staging launched |
| July 2025 | MEDITECH Expanse documentation API integration |
| October 2025 | Revenue cycle expansion (CPT, E/M codes) |
| October 2025 | Nursing consortium launched |

**Supported Order Types:**
- Prescription medications
- Laboratory orders
- Imaging orders (expansion planned)
- Referrals

**EHR Coverage:**
- âœ… athenahealth (GA)
- âœ… MEDITECH (GA)
- ğŸ”œ Epic (coming soon)
- ğŸ”œ Oracle Health (coming soon)

**Impact Metrics:**
- 72% faster note completion
- 9X ROI in year 1
- 48% reduction in amended encounters

**Sources:**
- [Suki Ambient Orders](https://www.businesswire.com/news/home/20250403618881/en/Suki-Unveils-Industry-First-Ambient-Orders-Staging-for-its-AI-Assistant)
- [Suki Revenue Cycle Expansion](https://www.suki.ai/news/smarter-codes-speedier-reimbursements-suki-supercharges-revenue-cycle-with-next-gen-ai/)

---

### 4.3 Other Vendor Approaches

**Ambient AI Scribe Market (2025):**

| Vendor | Market Share | Order Capabilities | Key Differentiator |
|--------|--------------|-------------------|-------------------|
| **Abridge** | ~30% | Epic co-development | Best in KLAS 2025, $5.3B valuation |
| **Nuance DAX** | Major | GA in Epic | Microsoft/Azure backing |
| **Ambience** | ~13% | Coding focus | 200+ specialties |
| **Suki** | Growing | First ambient orders | EHR-agnostic |
| **DeepScribe** | Specialty | E&M coding embedded | Oncology leader, 3.1M visits/year |
| **Nabla** | Growing | Emerging | Sub-20 second notes, privacy focus |

**Abridge:**
- Co-developing order entry with Epic Workshop program
- Captures orders discussed during conversations
- $300M Series E (2025), $5.3B valuation
- 150+ health systems, 50M projected clinical interactions (2025)

**Ambience Healthcare:**
- Focus on revenue integrity and coding
- 200+ specialty support including oncology, psychiatry, ED
- athenahealth marketplace integration
- Unicorn status achieved 2025

**DeepScribe:**
- 98.8 KLAS spotlight score (highest in category)
- Specialty focus: Oncology, Cardiology
- E&M coding suggestions embedded in notes
- Human QA step before notes returned to clinician

**Nabla:**
- Sub-20 second note generation
- Zero data storage (browser-only processing)
- Multilingual support
- Emerging agentic features

**Sources:**
- [Abridge Series E](https://www.fiercehealthcare.com/ai-and-machine-learning/ambient-ai-startup-abridge-scores-300m-series-e-backed-a16z-and-khosla)
- [DeepScribe Overview](https://www.deepscribe.ai/)
- [Nabla Features](https://www.nabla.com/)

---

### 4.4 EHR-Native vs Third-Party

**Competitive Landscape:**

```
EHR Native vs Third-Party AI:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  EHR-NATIVE (Emerging)              THIRD-PARTY (Dominant)      â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚  Epic (August 2025 announcement)    Abridge (~30% share)        â”‚
â”‚  â€¢ Native AI scribe                 Nuance DAX                  â”‚
â”‚  â€¢ Haiku/Canto recording            Ambience (~13% share)       â”‚
â”‚  â€¢ Dragon AI + Cosmos               Suki                        â”‚
â”‚  â€¢ Wider release 2026               DeepScribe                  â”‚
â”‚                                     Nabla                       â”‚
â”‚  Oracle Health (in development)                                 â”‚
â”‚  athenahealth (in development)                                  â”‚
â”‚                                                                 â”‚
â”‚  Current Reality (2025):                                        â”‚
â”‚  â€¢ Startups dominate 70% of AI scribing market                  â”‚
â”‚  â€¢ EHRs "striking back" with native solutions                   â”‚
â”‚  â€¢ Workshop partnerships blur native/third-party lines          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Selection Criteria:**

EHR integration is the **primary deciding factor** for healthcare organizations:

| Factor | Weight | Third-Party Advantage | EHR-Native Advantage |
|--------|--------|----------------------|---------------------|
| Integration depth | High | Workshop partnerships | Seamless native |
| Speed to market | High | Available now | 2026+ for most |
| Multi-EHR support | Medium | Cross-platform | Single EHR only |
| Feature innovation | Medium | Faster iteration | Slower, stable |
| Cost | Medium | Subscription | Bundled potential |
| Support | Medium | Specialized | Single vendor |

**Sources:**
- [EHR Integration Drives Purchasing](https://www.techtarget.com/searchhealthit/news/366614644/EHR-integration-drives-ambient-speech-purchasing-decisions)
- [2025 State of AI in Healthcare](https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/)

---

## 5. Safety Considerations

### 5.1 Wrong Order Risks

**Error Types and Causes:**

| Error Type | AI Risk Factor | Mitigation |
|------------|----------------|------------|
| Wrong patient | Ambient capture misattribution | Patient verification prompts |
| Wrong drug | Phonetic similarity, transcription errors | Drug name confirmation |
| Wrong dose | Unit confusion, weight errors | Range checking, BSA verification |
| Wrong frequency | Ambiguous language interpretation | Standardized frequency options |
| Omission | Failed to capture discussed order | Reconciliation prompts |
| Commission | Captured hypothetical/historical order | Intent classification |
| Wrong indication | Context misinterpretation | Indication verification |

**Known Limitations:**

From MEDIQA-OE 2025 benchmark:
- Best systems achieve only 81.8% match F1 score
- Description accuracy lags 15-18%
- Complex multi-step orders particularly challenging
- Rare conditions and edge cases underperform

**AI-Specific Risks:**
- Coding errors in algorithms leading to faulty decisions
- Failure to account for rare/complex conditions
- Black-box nature limits explainability
- Potential for hallucination of non-discussed orders

---

### 5.2 Verification Requirements

**Mandatory Human Oversight:**

All current AI order systems require clinician verification:

```
Verification Checkpoints:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  1. ORDER REVIEW                                                â”‚
â”‚     â€¢ Clinician reviews each AI-suggested order                 â”‚
â”‚     â€¢ Compares to patient discussion and clinical judgment      â”‚
â”‚                                                                 â”‚
â”‚  2. MODIFICATION                                                â”‚
â”‚     â€¢ Adjust dose, frequency, quantity as needed                â”‚
â”‚     â€¢ Select alternatives if suggestion inappropriate           â”‚
â”‚                                                                 â”‚
â”‚  3. CLINICAL DECISION SUPPORT                                   â”‚
â”‚     â€¢ Drug interaction alerts                                   â”‚
â”‚     â€¢ Allergy warnings                                          â”‚
â”‚     â€¢ Dosing guidance                                           â”‚
â”‚                                                                 â”‚
â”‚  4. AUTHENTICATION                                              â”‚
â”‚     â€¢ Clinician signature/authentication required               â”‚
â”‚     â€¢ Cannot be delegated to AI                                 â”‚
â”‚                                                                 â”‚
â”‚  5. SUBMISSION                                                  â”‚
â”‚     â€¢ Order transmitted to pharmacy/lab/imaging                 â”‚
â”‚     â€¢ Audit trail created                                       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Verification Best Practices:**
- Regular testing, validation, and monitoring of AI tool function
- Continuous validation by qualified healthcare professional
- Documentation of verification in medical record
- Mechanism to capture modifications from AI suggestions

---

### 5.3 Audit Trails

**Required Documentation:**

| Element | Purpose |
|---------|---------|
| AI suggestion timestamp | When order was generated |
| Original AI suggestion | What system proposed |
| Clinician modifications | Changes made by provider |
| Acceptance/rejection | Final disposition |
| Clinician identity | Who verified/signed |
| Authentication method | How identity confirmed |
| Submission timestamp | When order finalized |

**CHAI Standards Development:**

Coalition for Health Artificial Intelligence (CHAI) developing:
- Assurance Standards Guide
- Areas: diagnostic imaging, care management, EHR query/extraction with GenAI
- Responsible AI Checklist (RAIC) for evaluation

---

### 5.4 Liability

**Current Legal Framework:**

> "As the law currently stands, physicians and hospitals shoulder the burden of liability for AI-related errors."
> â€” Sara Gerke, University of Illinois

**Key Principles:**

1. **Physician Remains Liable**: Even when using AI, clinicians responsible for final decisions
2. **Clinical Judgment Required**: Blindly accepting AI recommendations increases liability exposure
3. **Evolving Standard of Care**: As AI becomes pervasive, not using validated AI tools could become liability
4. **Manufacturer Liability**: Limited under current framework, though evolving

**Federation of State Medical Boards (April 2024):**
> "Medical professionals are responsible for ensuring accuracy and veracity of evidence-based conclusions."

**Emerging Legal Considerations:**

| Scenario | Likely Liability |
|----------|------------------|
| AI suggests wrong drug, physician accepts without review | Physician |
| AI fails to flag interaction, causes harm | Shared (physician + potentially manufacturer) |
| Validated AI recommendation overridden, worse outcome | Potentially physician |
| AI malfunction causes erroneous suggestion | Manufacturer (if known defect) |

**Protective Measures:**
- Document AI tool version and validation status
- Maintain clear audit trails of verification
- Follow manufacturer guidelines
- Apply independent clinical judgment
- Stay informed of tool limitations

**Sources:**
- [Medical Economics - AI Malpractice](https://www.medicaleconomics.com/view/the-new-malpractice-frontier-who-s-liable-when-ai-gets-it-wrong-)
- [Healthcare Brew - AI Liability](https://www.healthcare-brew.com/stories/2025/04/01/doctors-liable-ai-mistake-malpractice)
- [NEJM - AI Liability](https://www.nejm.org/doi/full/10.1056/NEJMhle2308901)
- [PMC - AI Physician Liability](https://pmc.ncbi.nlm.nih.gov/articles/PMC12309835/)

---

## 6. Regulatory Framework

### 6.1 FDA Status

**2025 FDA Guidance Documents:**

**January 2025: AI-Enabled Device Software Functions Lifecycle Management**
- Recommendations for marketing applications
- Design, development, implementation guidance
- Total Product Lifecycle (TPLC) approach
- Post-market performance monitoring

**Key FDA Requirements:**

| Requirement | Description |
|-------------|-------------|
| Transparency | Clear statement device uses AI, plain-language description |
| Inputs/Outputs | Details on model data flow and system interactions |
| Performance Measures | Documented metrics and known risks |
| Bias Documentation | Potential sources of bias identified |
| PCCP | Predetermined Change Control Plan for learning systems |

**Predetermined Change Control Plans (PCCP):**

Allows manufacturers to implement algorithm updates without new submissions:

```
PCCP Components:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  1. Description of Modifications                                â”‚
â”‚     â€¢ Types of changes algorithm may make                       â”‚
â”‚     â€¢ Boundaries of automated learning                          â”‚
â”‚                                                                 â”‚
â”‚  2. Modification Protocol                                       â”‚
â”‚     â€¢ How changes will be implemented                           â”‚
â”‚     â€¢ Validation requirements for changes                       â”‚
â”‚                                                                 â”‚
â”‚  3. Impact Assessment                                           â”‚
â”‚     â€¢ Benefits and risks of modification types                  â”‚
â”‚     â€¢ Bias mitigation strategies                                â”‚
â”‚     â€¢ Must remain within intended use                           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Clinical Decision Support Software:**

Under 21st Century Cures Act, CDS software exempt from FDA device regulation if:
- Not intended to acquire, process, or analyze medical data
- Supports but does not replace clinical decision-making
- Allows providers to independently review and understand recommendation basis
- Used in non-urgent settings

**Market Statistics:**
- **1,250+ AI-enabled devices** authorized by FDA (July 2025)
- Up from 950 devices (August 2024)
- ~100 new approvals per year

**2025 FDA Initiatives:**
- External Policy Council for AI principles
- Internal Use Council for FDA AI applications
- September 2025: Request for comment on real-world performance measurement

**Sources:**
- [FDA AI Guidance](https://www.fda.gov/media/189391/download)
- [FDA AI Device Framework](https://intuitionlabs.ai/articles/ai-medical-devices-regulation-2025)
- [Bipartisan Policy Center - FDA Oversight](https://bipartisanpolicy.org/issue-brief/fda-oversight-understanding-the-regulation-of-health-ai-tools/)

---

### 6.2 EPCS Requirements

**Electronic Prescribing for Controlled Substances (EPCS):**

**CMS EPCS Program (2025):**

| Requirement | Threshold |
|-------------|-----------|
| Compliance Rate | 70% or higher for Part D Schedule II-V |
| Measurement | Based on NPI prescription claims |
| Small Prescriber Exception | â‰¤100 qualifying prescriptions/year |
| LTC Facility Exception | Until January 1, 2028 |

**DEA Technical Requirements (21 CFR Part 1311 Subpart C):**

| Requirement | Specification |
|-------------|---------------|
| Digital Signatures | Cryptographic signatures required |
| Authentication | Two-factor authentication mandatory |
| Cryptographic Standards | FIPS 140-2 validated modules |
| Identity Proofing | NIST IAL2 level required |
| Remote Identity Proofing | Real-time two-way audio-visual permitted |

**Current Adoption (2024):**
- 16%+ of prescribers not enabled for e-prescribing
- 4% of pharmacies non-compliant
- Compliance improving but gaps remain

**AI in EPCS:**
- No specific AI requirements in current EPCS regulations
- AI primarily used for documentation leading to prescriptions
- Human authentication remains mandatory for controlled substances
- Potential future use: fraud detection, pattern analysis

**Sources:**
- [CMS EPCS Program](https://www.cms.gov/medicare/e-health/eprescribing/cms-eprescribing-for-controlled-substances-program)
- [DEA EPCS Q&A](https://www.deadiversion.usdoj.gov/faq/epcs-faq.html)
- [EPCS State Requirements](https://www.rxnt.com/epcs-mandates/)

---

### 6.3 International Regulations

**European Union: AI Act + MDR/IVDR**

**Timeline:**
| Date | Requirement |
|------|-------------|
| August 2024 | AI Act entered into force |
| February 2025 | Prohibited AI practices provisions apply |
| May 2025 | General-purpose AI obligations apply |
| August 2026 | Full compliance for most high-risk AI |
| August 2027 | High-risk medical device AI compliance |

**High-Risk AI Classification:**

AI-based medical devices classified as high-risk under AI Act:
- Must meet risk-mitigation requirements
- High-quality data set requirements
- Clear user information obligations
- Human oversight requirements
- Bias mitigation and documentation

**Dual Compliance (MDR/IVDR + AI Act):**

```
EU Medical Device AI Compliance:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Medical Device Regulation (MDR/IVDR)                           â”‚
â”‚  â€¢ Risk classification under device rules                       â”‚
â”‚  â€¢ Clinical evidence requirements                               â”‚
â”‚  â€¢ Conformity assessment                                        â”‚
â”‚  â€¢ Notified body involvement                                    â”‚
â”‚                                                                 â”‚
â”‚  + AI Act Requirements (Parallel)                               â”‚
â”‚  â€¢ AI-specific risk management                                  â”‚
â”‚  â€¢ Data governance and bias mitigation                          â”‚
â”‚  â€¢ Transparency and human oversight                             â”‚
â”‚  â€¢ Fundamental rights assessment                                â”‚
â”‚                                                                 â”‚
â”‚  Note: AI Act doesn't change MDR/IVDR risk class                â”‚
â”‚  but adds additional AI-specific requirements                   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Clinical Evidence Requirements:**

High-risk medical device AI must demonstrate:
- Safety and performance through clinical evidence
- Generated through clinical investigation or performance study
- Verification that AI doesn't infringe fundamental rights
- Representative training data for intended patient population

**Current Status (October 2025):**
- No organizations yet designated as AI Act notified bodies
- Expected: MDR/IVDR notified bodies will extend scope to AI Act

**Other International:**

| Jurisdiction | Status |
|--------------|--------|
| UK | Post-Brexit framework, MHRA guidance |
| Canada | Health Canada AI guidance evolving |
| Australia | TGA medical device AI framework |
| Japan | PMDA AI medical device guidance |

**Sources:**
- [EU AI Act Overview](https://www.europarl.europa.eu/topics/en/article/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence)
- [MDCG/AIB Joint Guidance](https://health.ec.europa.eu/document/download/b78a17d7-e3cd-4943-851d-e02a2f22bbb4_en)
- [AI Act Medical Device Implications](https://www.nature.com/articles/s41746-024-01232-3)

---

## 7. Market Outlook and Trends

### 7.1 Market Size and Growth

| Metric | 2025 | 2030 (Projected) | CAGR |
|--------|------|------------------|------|
| Global Ambient Intelligence Market | $37.2B | $91B+ | 20% |
| AI Medical Scribes Adoption | 60% of providers | Near-universal | - |
| AI Prior Auth Market | Growing rapidly | Multi-billion | - |

### 7.2 Key 2025 Developments

**Q1 2025:**
- FDA AI lifecycle management guidance released
- MEDIQA-OE 2025 order extraction benchmark launched

**Q2 2025:**
- Suki ambient orders staging GA
- Abridge Series E ($300M, $5.3B valuation)

**Q3 2025:**
- Suki MEDITECH integration
- Epic native AI scribe announcement
- FDA real-world performance comment request

**Q4 2025:**
- CMS WISeR pilot vendor selection
- Dragon Copilot GA (US)
- Suki revenue cycle expansion
- International DAX expansion

### 7.3 Future Directions

**2026 and Beyond:**
- Epic native AI scribe wider release
- EU AI Act full compliance requirements
- CMS WISeR pilot launch
- Deeper order automation with tighter verification workflows
- Expanded specialty support
- Multi-modal AI (voice + vision + text)
- Agentic AI capabilities for complex workflows

---

## 8. Recommendations

### For Health Systems Evaluating AI Order Tools:

1. **Prioritize EHR Integration**: Workshop partnerships with Epic, Oracle, MEDITECH offer deepest integration
2. **Verify Safety Workflows**: Ensure mandatory clinician verification before order submission
3. **Assess Specialty Needs**: Different vendors excel in different specialties (DeepScribe for oncology, etc.)
4. **Plan for Regulation**: Consider EU AI Act compliance if operating internationally
5. **Document Everything**: Establish audit trail practices before implementation
6. **Train Clinicians**: Education on AI limitations, verification requirements, liability

### For Vendors:

1. **Close the Accuracy Gap**: MEDIQA-OE shows 18%+ improvement opportunity
2. **Expand EHR Coverage**: Multi-EHR support differentiates in fragmented market
3. **Address Alert Fatigue**: AI optimization of CDS alerts critical for adoption
4. **Prepare for Regulation**: FDA PCCP and EU AI Act compliance becoming mandatory
5. **Transparency**: Explainable AI increasingly expected by regulators and users

---

## References

### Primary Sources

1. [Nuance DAX Copilot](https://www.nuance.com/healthcare/dragon-ai-clinical-solutions/dax-copilot.html)
2. [Suki Ambient Orders](https://www.suki.ai/news/suki-unveils-industry-first-ambient-orders-staging-for-its-ai-assistant/)
3. [MEDIQA-OE 2025](https://arxiv.org/html/2510.26974)
4. [FDA AI Guidance](https://www.fda.gov/media/189391/download)
5. [CMS WISeR Model](https://www.cms.gov/priorities/innovation/innovation-models/wiser)
6. [EU AI Act](https://www.europarl.europa.eu/topics/en/article/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence)
7. [CMS EPCS Program](https://www.cms.gov/medicare/e-health/eprescribing/cms-eprescribing-for-controlled-substances-program)

### Vendor Sources

8. [Abridge](https://www.abridge.com/product)
9. [Ambience Healthcare](https://www.ambiencehealthcare.com/)
10. [DeepScribe](https://www.deepscribe.ai/)
11. [Nabla](https://www.nabla.com/)

### Research and Analysis

12. [NEJM Catalyst - Ambient AI Scribes](https://catalyst.nejm.org/doi/full/10.1056/CAT.23.0404)
13. [Healthcare IT News - AI Roundup](https://www.healthcareitnews.com/news/ai-roundup-ambient-recording-emergencies-and-more-ehr-enhancements)
14. [Menlo Ventures - State of AI Healthcare](https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/)
15. [Medical Economics - AI Malpractice](https://www.medicaleconomics.com/view/the-new-malpractice-frontier-who-s-liable-when-ai-gets-it-wrong-)

---

*Document generated: November 2025*
*Research scope: AI order and prescription capabilities as of Q4 2025*
